RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors

Endocrine Reviews

Volumn 27, Issue 5, 2006, Pages 535-560

  De Groot, Jan Willem B ^a   Links, Thera P ^a   Plukker, John T M ^a   Lips, Cornelis J M ^b   Hofstra, Robert M W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CARBAZOLE DERIVATIVE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMATINIB; IODINE 131; MONOCLONAL ANTIBODY; PROTEIN RET; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SUNITINIB; VANDETANIB;

AUTOPHOSPHORYLATION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DIMERIZATION; DISSECTION; DRUG INHIBITION; EMBRYO DEVELOPMENT; ENDOCRINE TUMOR; GENE THERAPY; GENETIC DISORDER; GENETIC POLYMORPHISM; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NEUROFIBROMATOSIS; NONHUMAN; ONCOCYTOMA; ONCOGENE RAS; PHENOTYPE; PHEOCHROMOCYTOMA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION; SIPPLE SYNDROME; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ENDOCRINE GLAND NEOPLASMS; FETAL DEVELOPMENT; GENE TARGETING; GENE THERAPY; HAPLOTYPES; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION;

EID: 33747080744     PISSN: 0163769X     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2006-0017     Document Type: Review

References (305)

1. Vlahovic G, Crawford J 2003 Activation of tyrosine kinases in cancer. Oncologist 8:531-538
2. Blume-Jensen P, Hunter T 2001 Oncogenic kinase signalling. Nature 411:355-365
3. Pachnis V, Mankoo B, Costantini F 1993 Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 119:1005-1017
4. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V 1994 Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor RET. Nature 367:380-383
5. Airaksinen MS, Saarma M 2002 The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3:383-394
6. Manie S, Santoro M, Fusco A, Billaud M 2001 The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet 17:580-589
7. Santoro M, Rosati R, Grieco M, Berlingieri MT, D'Amato GL, de Franciscis V, Fusco A 1990 The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 5:1595-1598
8. Ikeda I, Ishizaka Y, Tahira T, Suzuki T, Onda M, Sugimura T, Nagao M 1990 Specific expression of the ret proto-oncogene in human neuroblastoma cell lines. Oncogene 5:1291-1296
9. Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL 2000 Molecular basis of Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85:878-882
10. Takahashi M, Ritz J, Cooper GM 1985 Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell 42:581-588
11. Pasini B, Hofstra RM, Yin L, Bocciardi R, Santamaria G, Grootscholten PM, Ceccherini I, Patrone G, Priolo M, Buys CH, Romeo G 1995 The physical map of the human RET proto-oncogene. Oncogene 11:1737-1743
12. Anders J, Kjar S, Ibanez CF 2001 Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J Biol Chem 276:35808-35817
13. Takahashi M, Buma Y, Taniguchi M 1991 Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells. Oncogene 6:297-301
14. Takahashi M, Asai N, Iwashita T, Isomura T, Miyazaki K, Matsuyama M 1993 Characterization of the RET proto-oncogene products expressed in mouse L cells. Oncogene 8:2925-2929
15. Myers SM, Eng C, Ponder BA, Mulligan LM 1995 Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 11:2039-2045
16. Airaksinen MS, Titievsky A, Saarma M 1999 GDNF family neurotrophic factor signaling: four masters, one servant? Mol Cell Neurosci 13:313-325
17. Yu T, Scully S, Yu Y, Fox GM, Jing S, Zhou R 1998 Expression of GDNF family receptor components during development: implications in the mechanisms of interaction. J Neurosci 18:4684-4696
18. Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrock BW, Fox GM 1996 GDNF-induced activation of the RET protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell 85:1113-1124
19. Baloh RH, Enomoto H, Johnson Jr EM, Milbrandt J 2000 The GDNF family ligands and receptors: implications for neural development. Curr Opin Neurobiol 10:103-110
20. Kjaer S, Ibanez CF 2003 Identification of a surface for binding to the GDNF-GFR α1 complex in the first cadherin-like domain of RET. J Biol Chem 278:47898-47904
21. Paratcha G, Ledda F, Baars L, Coulpier M, Besset V, Anders J, Scott R, Ibanez CF 2001 Released GFRα1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts. Neuron 29:171-184
22. Tsui-Pierchala BA, Encinas M, Milbrandt J, Johnson Jr EM 2002 Lipid rafts in neuronal signaling and function. Trends Neurosci 25:412-417
23. Simons K, Toomre D 2000 Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1:31-39
24. Tansey MG, Baloh RH, Milbrandt J, Johnson Jr EM 2000 GFRα-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival. Neuron 25:611-623
25. Encinas M, Tansey MG, Tsui-Pierchala BA, Comella JX, Milbrandt J, Johnson Jr EM 2001 c-Src is required for glial cell linederived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. J Neurosci 21:1464-1472
26. Kato M, Takeda K, Kawamoto Y, Iwashita T, Akhand AA, Senga T, Yamamoto M, Sobue G, Hamaguchi M, Takahashi M, Nakashima I 2002 Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine. Cancer Res 62:2414-2422
27. Yang J, Lindahl M, Lindholm P, Virtanen H, Coffey E, Runeberg-Roos P, Saarma M 2004 PSPN/GFRα4 has a significantly weaker capacity than GDNF/GFRα1 to recruit RET to rafts, but promotes neuronal survival and neurite outgrowth. FEBS Lett 569:267-271
28. Coulpier M, Anders J, Ibanez CF 2002 Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival. J Biol Chem 277:1991-1999
29. Tsui-Pierchala BA, Milbrandt J, Johnson Jr EM 2002 NGF utilizes c-Ret via a novel GFL-independent, inter-RTK signaling mechanism to maintain the trophic status of mature sympathetic neurons. Neuron 33:261-273
30. Liu X, Vega QC, Decker RA, Pandey A, Worby CA, Dixon JE 1996 Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J Biol Chem 271:5309-5312
31. Santoro M, Carlomagno F, Melillo RM, Fusco A 2004 Dysfunction of the RET receptor in human cancer. Cell Mol Life Sci 61:2954-2964
32. Ichihara M, Murakumo Y, Takahashi M 2004 RET and neuroendocrine tumors. Cancer Lett 204:197-211
33. Fukuda T, Kiuchi K, Takahashi M 2002 Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase. J Biol Chem 277:19114-19121
34. Lin TS, Mahajan S, Frank DA 2000 STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19:2496-2504
35. Schuringa JJ, Wojtachnio K, Hagens W, Vellenga E, Buys CH, Hofstra RM, Kruijer W 2001 MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 20:5350-5358
36. Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM 2005 RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 65:1729-1737
37. Iwashita T, Asai N, Murakami H, Matsuyama M, Takahashi M 1996 Identification of tyrosine residues that are essential for transforming activity of the RET proto-oncogene with MEN2A or MEN2B mutation. Oncogene 12:481-487
38. Kawamoto Y, Takeda K, Okuno Y, Yamakawa Y, Ito Y, Taguchi R, Kato M, Suzuki H, Takahashi M, Nakashima I 2004 Identification of RET autophosphorylation sites by mass spectrometry. J Biol Chem 279:14213-14224
39. Encinas M, Crowder RJ, Milbrandt J, Johnson Jr EM 2004 Tyrosine 981, a novel RET autophosphorylation site, binds c-Src to mediate neuronal survival. J Biol Chem 279:18262-18269
40. Panta GR, Nwariaku F, Kim LT 2004 RET signals through focal adhesion kinase in medullary thyroid cancer cells. Surgery 136:1212-1217
41. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC 2005 The role of focal-adhesion kinase in cancer: a new therapeutic opportunity. Nat Rev Cancer 5:505-515
42. Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P, Radice MT, Pierotti MA 1996 The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cγ. Mol Cell Biol 16:2151-2163
43. Knauf JA, Ouyang B, Croyle M, Kimura E, Fagin JA 2003 Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCε in PCCL3 thyroid cells. Oncogene 22:6830-6838
44. Andreozzi F, Melillo RM, Carlomagno F, Oriente F, Miele C, Fiory F, Santopietro S, Castellone MD, Beguinot F, Santoro M, Formisano P 2003 Protein kinase Cα activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase. Oncogene 22:2942-2949
45. Nozaki C, Asai N, Murakami H, Iwashita T, Iwata Y, Horibe K, Klein RD, Rosenthal A, Takahashi M 1998 Calcium-dependent Ret activation by GDNF and neurturin. Oncogene 16:293-299
46. van Weering DH, Moen TC, Braakman I, Baas PD, Bos JL 1998 Expression of the receptor tyrosine kinase Ret on the plasma membrane is dependent on calcium. J Biol Chem 273:12077-12081
47. Asai N, Murakami H, Iwashita T, Takahashi M 1996 A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins. J Biol Chem 271:17644-17649
48. Segouffin-Cariou C, Billaud M 2000 Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 275:3568-3576
49. Murakami H, Iwashita T, Asai N, Shimono Y, Iwata Y, Kawai K, Takahashi M 1999 Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by RET with the MEN 2B mutation. Biochem Biophys Res Commun 262:68-75
50. Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG, Pierotti MA 1998 Grb2 binding to the different isoforms of Ret tyrosine kinase. Oncogene 17:1079-1087
51. Scott RP, Eketjall S, Aineskog H, Ibanez CF 2005 Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase. J Biol Chem 280:13442-13449
52. Pelicci G, Troglio F, Bodini A, Melillo RM, Pettirossi V, Coda L, De Giuseppe A, Santoro M, Pelicci PG 2002 The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 22:7351-7363
53. Melillo RM, Carlomagno F, De Vita G, Formisano P, Vecchio G, Fusco A, Billaud M, Santoro M 2001 The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. Oncogene 20:209-218
54. Takahashi M 2001 The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12:361-373
55. Murakami H, Iwashita T, Asai N, Iwata Y, Narumiya S, Takahashi M 1999 Rho-dependent and -independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130Cas mediated by Ret kinase. Oncogene 18:1975-1982
56. Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K, Kurokawa K, Murakumo Y, Imai T, Funahashi H, Nakao A, Takahashi M 2000 Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19:4469-4475
57. Kurokawa K, Iwashita T, Murakami H, Hayashi H, Kawai K, Takahashi M 2001 Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction. Oncogene 20:1929-1938
58. Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I 2001 Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Mol Cell Biol 21:4177-4187
59. Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, Nagasaka T, Murakumo Y, Murakami H, Sugiura H, Iwata H, Ishiguro N, Takahashi M 2002 Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am J Pathol 161:249-256
60. Xia Y, Karin M 2004 The control of cell motility and epithelial morphogenesis by Jun kinases. Trends Cell Biol 14:94-101
61. Kennedy NJ, Davis RJ 2003 Role of JNK in tumor development. Cell Cycle 2:199-201
62. Murakami H, Yamamura Y, Shimono Y, Kawai K, Kurokawa K, Takahashi M 2002 Role of Dok1 in cell signaling mediated by RET tyrosine kinase. J Biol Chem 277:32781-32790
63. Grimm J, Sachs M, Britsch S, Di Cesare S, Schwarz-Romond T, Alitalo K, Birchmeier W 2001 Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation. J Cell Biol 154:345-354
64. Schuetz G, Rosario M, Grimm J, Boeckers TM, Gundelfinger ED, Birchmeier W 2004 The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells. J Cell Biol 167:945-952
65. Durick K, Gill GN, Taylor SS 1998 Shc and Enigma are both required for mitogenic signaling by Ret/ptc2. Mol Cell Biol 18:2298-2308
66. Hayashi Y, Iwashita T, Murakamai H, Kato Y, Kawai K, Kurokawa K, Tohnai I, Ueda M, Takahashi M 2001 Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation. Biochem Biophys Res Commun 281:682-689
67. Ludwig L, Kessler H, Hoang-Vu C, Dralle H, Adler G, Boehm BO, Schmid RM 2003 Grap-2, a novel RET binding protein, is involved in RET mitogenic signaling. Oncogene 22:5362-5366
68. Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M 2003 RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1. Mol Endocrinol 17:1382-1394
69. Ledda F, Paratcha G, Ibanez CF 2002 Target-derived GFRα1 as an attractive guidance signal for developing sensory and sympathetic axons via activation of Cdk5. Neuron 36:387-401
70. Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WK, Heitz PU 1996 RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 81:2041-2046
71. Guo ZS, Bartlett DL 2004 Vaccinia as a vector for gene delivery. Expert Opin Biol Ther 4:901-917
72. Jain S, Watson MA, DeBenedetti MK, Hiraki Y, Moley JF, Milbrandt J 2004 Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. Cancer Res 64:3907-3913
73. Arighi E, Borrello MG, Sariola H 2005 RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 16:441-467
74. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, Kajita H, Takahashi M 1999 Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 18:3919-3922
75. de Graaff E, Srinivas S, Kilkenny C, D'Agati V, Mankoo BS, Costantini F, Pachnis V 2001 Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev 15:2433-2444
76. Sherman SI, Angelos P, Ball DW, Beenken SW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson Jr JA, Ridge JA, Robbins R, Shah JP, Sisson JC, Thompson NW 2005 Thyroid carcinoma. J Natl Compr Canc Netw 3:404-457
77. Fagin JA 2002 Minireview: branded from the start: distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 16:903-911
78. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262
79. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, Nupponen NN, Franssila K, Joensuu H 2005 MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol 29:544-549
80. Links TP, van Tol KM, Meerman GJ, de Vries EG 2001 Differentiated thyroid carcinoma: a polygenic disease. Thyroid 11:1135-1140
81. Pierotti MA, Vigneri P, Bongarzone I 1998 Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Recent Results Cancer Res 154:237-247
82. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G 1990 PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557-563
83. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE 2000 Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290:138-141
84. Smanik PA, Furminger TL, Mazzaferri EL, Jhiang SM 1995 Breakpoint characterization of the RET/PTC oncogene in human papillary thyroid carcinoma. Hum Mol Genet 4:2313-2318
85. Tallini G, Asa SL 2001 RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 8:345-354
86. Saenko V, Rogounovitch T, Shimizu-Yoshida Y, Abrosimov A, Lushnikov E, Roumiantsev P, Matsumoto N, Nakashima M, Meirmanov S, Ohtsuru A, Namba H, Tsyb A, Yamashita S 2003 Novel tumorigenic rearrangement, Δrfp/ret, in a papillary thyroid carcinoma from externally irradiated patient. Mutat Res 527:81-90
87. Nikiforov YE 2002 RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3-16
88. Baloch ZW, Livolsi VA 2005 Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow. Expert Rev Mol Diagn 5:573-584
89. Ito T, Seyama T, Iwamoto KS, Hayashi T, Mizuno T, Tsuyama N, Dohi K, Nakamura N, Akiyama M 1993 In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res 53:2940-2943
90. Fagin JA 2004 How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183:249-256
91. Goulko GM, Chepurny NI, Jacob P, Kairo IA, Likhtarev IA, Prohl G, Sobolev BG 1998 Thyroid dose and thyroid cancer incidence after the Chernobyl accident: assessments for the Zhytomyr region (Ukraine). Radiat Environ Biophys 36:261-273
92. Jacob P, Goulko G, Heidenreich WF, Likhtarev I, Kairo I, Tronko ND, Bogdanova TI, Kenigsberg J, Buglova E, Drozdovitch V, Golovneva A, Demidchik EP, Balonov M, Zvonova I, Beral V 1998 Thyroid cancer risk to children calculated. Nature 392:31-32
93. Williams D 2002 Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer 2:543-549
94. Collins BJ, Chiappetta G, Schneider AB, Santoro M, Pentimalli F, Fogelfeld L, Gierlowski T, Shore-Freedman E, Jaffe G, Fusco A 2002 RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. J Clin Endocrinol Metab 87:3941-3946
95. Santoro M, Melillo RM, Grieco M, Berlingieri MT, Vecchio G, Fusco A 1993 The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ 4:77-84
96. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, Xing S, Ledent C 1996 Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137:375-378
97. Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo G, Picone A, Portella G, Santelli G, Vecchio G, Fusco A 1996 Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12:1821-1826
98. Powell Jr DJ, Russell J, Nibu K, Li G, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A, Rothstein JL 1998 The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 58:5523-5528
99. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL 1998 Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 83:4116-4122
100. Cerilli LA, Mills SE, Rumpel CA, Dudley TH, Moskaluk CA 2002 Interpretation of RET immunostaining in follicular lesions of the thyroid. Am J Clin Pathol 118:186-193
101. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A 1998 RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4:287-294
102. Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A, Carcangiu ML, Fusco A, Tallini G 2002 RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 87:370-379
103. Puxeddu E, Moretti S, Giannico A, Martinelli M, Marino C, Avenia N, Cristofani R, Farabi R, Reboldi G, Ribacchi R, Pontecorvi A, Santeusanio F 2003 Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur J Endocrinol 148:505-513
104. Cetta F, Pelizzo MR, Curia MC, Barbarisi A 1999 Genetics and clinicopathological findings in thyroid carcinomas associated with familial adenomatous polyposis. Am J Pathol 155:7-9
105. Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED, Tronko ND, Bogdanova TI, Chiappetta G, Viglietto G, Pentimalli F, Salvatore G, Fusco A, Santoro M, Vecchio G 1999 High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab 84:4232-4238
106. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA 1998 RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 4:223-228
107. Basolo F, Giannini R, Monaco C, Melillo RM, Carlomagno F, Pancrazi M, Salvatore G, Chiappetta G, Pacini F, Elisei R, Miccoli P, Pinchera A, Fusco A, Santoro M 2002 Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol 160:247-254
108. Sheils OM, O'eary JJ, Uhlmann V, Lattich K, Sweeney EC 2000 RET/PTC-1 activation in Hashimoto thyroiditis. Int J Surg Pathol 8:185-189
109. Di Pasquale M, Rothstein JL, Palazzo JP 2001 Pathologic features of Hashimoto's-associated papillary thyroid carcinomas. Hum Pathol 32:24-30
110. Nikiforova MN, Caudill CM, Biddinger P, Nikiforov YE 2002 Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol 10:15-22
111. Corvi R, Lesueur F, Martinez-Alfaro M, Zini M, Decaussin M, Murat A, Romeo G 2001 RET rearrangements in familial papillary thyroid carcinomas. Cancer Lett 170:191-198
112. Alsanea O, Wada N, Ain K, Wong M, Taylor K, Ituarte PH, Treseler PA, Weier HU, Freimer N, Siperstein AE, Duh QY, Takami H, Clark OH 2000 Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery 128:1043-1050
113. Lesueur F, Stark M, Tocco T, Ayadi H, Delisle MJ, Goldgar DE, Schlumberger M, Romeo G, Canzian F 1999 Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium. J Clin Endocrinol Metab 84:2157-2162
114. Yutan E, Clark OH 2001 Hurthle cell carcinoma. Curr Treat Options Oncol 2:331-335
115. Kushchayeva Y, Duh QY, Kebebew E, Clark OH 2004 Prognostic indications for Hurthle cell cancer. World J Surg 28:1266-1270
116. Hunt JL 2005 Unusual thyroid tumors: a review of pathologic and molecular diagnosis. Expert Rev Mol Diagn 5:725-734
117. Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, Lazzi S, Monaco M, Mazzuchelli L, Tosi P, Santoro M, Fusco A 2002 The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 87:364-369
118. Musholt PB, Imkamp F, von Wasielewski R, Schmid KW, Musholt TJ 2003 RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hurthle cell carcinomas? Surgery 134:881-889
119. Bunone G, Uggeri M, Mondellini P, Pierotti MA, Bongarzone I 2000 RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Res 60:2845-2849
120. Pierotti MA, Bongarzone I, Borello MG, Greco A, Pilotti S, Sozzi G 1996 Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer 16:1-14
121. Melillo RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta G, Fusco A, Carlomagno F, Picascia A, Tramontano D, Tallini G, Santoro M 2004 The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol 165:511-521
122. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115:1068-1081
123. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M 2001 Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61:6105-6111
124. Jung HS, Kim DW, Jo YS, Chung HK, Song JH, Park JS, Park KC, Park SH, Hwang JH, Jo KW, Shong M 2005 Regulation of PKB tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol Endocrinol 19:2748-2759
125. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, Burman KD, De Micco C, Ringel MD 2004 Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 41:161-170
126. Castellone MD, Celetti A, Guarino V, Cirafici AM, Basolo F, Giannini R, Medico E, Kruhoffer M, Orntoft TF, Curcio F, Fusco A, Melillo RM, Santoro M 2004 Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene 23:2188-2196
127. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M 2005 Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab 90:5270-5278
128. Miyagi E, Braga-Basaria M, Hardy E, Vasko V, Burman KD, Jhiang S, Saji M, Ringel MD 2004 Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol Carcinog 41:98-107
129. Rhoden KJ, Johnson C, Brandao G, Howe JG, Smith BR, Tallini G 2004 Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Lab Invest 84:1557-1570
130. Heinlein CA, Ting HJ, Yeh S, Chang C 1999 Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor γ. J Biol Chem 274:16147-16152
131. Abbosh PH, Nephew KP 2005 Multiple signaling pathways converge on β-catenin in thyroid cancer. Thyroid 15:551-561
132. Phay JE, Moley JF, Lairmore TC 2000 Multiple endocrine neoplasias. Semin Surg Oncol 18:324-332
133. Mathew CGP, Chin KS, Easton DF, Thorpe K, Carter C, Liou GI, Fong S-L, Bridges CDB, Haak H, Nieuwenhuijzen-Kruseman AC, Schifter S, Hansen HH, Telenius H, Telenius-Berg M, Ponder BAJ 1987 A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328:527-528
134. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460
135. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells Jr SA 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856
136. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Yin L, Pasini B, Höppener JWM, Ploos van Amstel HK, Romeo G, Lips CJM, Buys CHCM 1994 A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376
137. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells Jr SA, Goodfellow PJ, Donis-Keller H 1994 Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 91:1579-1583
138. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GFW, Jackson CE, Tunnacliffe A, Ponder BAJ 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237-241
139. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis. JAMA 276:1575-1579
140. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells Jr SA, Marx SJ 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671
141. Machens A, Dralle H 2006 Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside. Mol Cell Endocrinol 247:34-40
142. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M 1997 Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 57:2870-2872
143. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H; European Multiple Endocrine Neoplasia (EUROMEN) Study Group 2003 Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517-1525
144. Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K, Yamaguchi K 1999 Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 90:1-5
145. Menko FH, van der Luijt RB, de Valk IA, Toorians AW, Sepers JM, van Diest PJ, Lips CJ 2002 Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J Clin Endocrinol Metab 87:393-397
146. Eng C, Mulligan LM 1997 Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mutat 9:97-109
147. Dvorakova S, Vaclavikova E, Duskova J, Vlcek P, Ryska A, Bendlova B 2005 Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germline mutation Gly321Arg. J Endocrinol Invest 28:905-909
148. Da Silva AM, Maciel RM, Da Silva MR, Toledo SR, De Carvalho MB, Cerutti JM 2003 A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88:5438-5443
149. Saez ME, Ruiz A, Cebrian A, Morales F, Robledo M, Antinolo G, Borrego S 2000 A new germline mutation, R600Q, within the coding region of RET proto-oncogene: a rare polymorphism or a MEN 2 causing mutation? Hum Mutat 15:122
150. Rey JM, Brouillet JP, Fonteneau-Allaire J, Boneu A, Bastie D, Maudelonde T, Pujol P 2001 Novel germline RET mutation segregating with papillary thyroid carcinomas. Genes Chromosomes Cancer 32:390-391
151. Wiench M, Wygoda Z, Gubala E, Wloch J, Lisowska K, Krassowski J, Scieglinska D, Fiszer-Kierzkowska A, Lange D, Kula D, Zeman M, Roskosz J, Kukulska A, Krawczyk Z, Jarzab B 2001 Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 19:1374-1380
152. Ahmed SA, Snow-Bailey K, Highsmith WE, Sun W, Fenwick RG, Mao R 2005 Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases. J Mol Diagn 7:283-288
153. Aiello A, Cioni K, Gobbo M, Collini P, Gullo M, Della Torre G, Passerini E, Ferrando B, Pilotti S, Pierotti MA, Pasini B 2005 The familial medullary thyroid carcinoma-associated RET E768D mutation in a multiple endocrine neoplasia type 2A case. Surgery 137:574-576
154. D'Aloiso L, Carlomagno F, Bisceglia M, Anaganti S, Ferretti E, Verrienti A, Arturi F, Scarpelli D, Russo D, Santoro M, Filetti S 2006 Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant non-aggressive familial medullary thyroid carcinoma. J Clin Endocrinol Metab 91:754-759
155. Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, Nakano K, Kuma K, Futami H, Yamaguchi K 2002 Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg 26:1023-1028
156. Maschek W, Pichler R, Rieger R, Weinhausel A, Berg J 2002Anew identified germline mutation of the RET proto-oncogene responsible for familial medullary thyroid carcinoma in co-existence with a hyperfunctioning autonomous nodule. Clin Endocrinol (Oxf) 56:823
157. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter MM, Hoppner W 1998 A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770-774
158. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, Tournaire J, Lenoir GM, Romeo G 1995 RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415-2419
159. Nilsson O, Tisell LE, Jansson S, Ahlman H, Gimm O, Eng C 1999 Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. JAMA 281:1587-1588
160. Demeester R, Parma J, Cochaux P, Vassart G, Abramowicz MJ 2001 A rare variant, I852M, of the RET proto-oncogene in a patient with medullary thyroid carcinoma at age 20 years. Hum Mutat 17:354
161. Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CH 1997 A novel point mutation in the intracellular domain of the RET protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176-4178
162. Jimenez C, Habra MA, Huang SC, El Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF 2004 Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab 89:4142-4145
163. Jimenez C, Dang GT, Schultz PN, El Naggar A, Shapiro S, Barnes EA, Evans DB, Vassilopoulou-Sellin R, Gagel RF, Cote GJ, Hoff AO 2004 A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 89:3521-3526
164. Poturnajova M, Altanerova V, Kostalova L, Breza J, Altaner C 2005 Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome. J Mol Med 83:287-295
165. Nunes AB, Ezabella MC, Pereira AC, Krieger JE, Toledo SP 2002 A novel Val648Ile substitution in RET protooncogene observed in a Cys634Arg multiple endocrine neoplasia type 2A kindred presenting with an adrenocorticotropin- producing pheochromocytoma. J Clin Endocrinol Metab 87:5658-5661
166. Tessitore A, Sinisi AA, Pasquali D, Cardone M, Vitale D, Bellastella A, Colantuoni V 1999 A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene. J Clin Endocrinol Metab 84:3522-3527
167. Bartsch DK, Hasse C, Schug C, Barth P, Rothmund M, Hoppner W 2000 A RET double mutation in the germline of a kindred with FMTC. Exp Clin Endocrinol Diabetes 108:128-132
168. Pigny P, Bauters C, Wemeau JL, Houcke ML, Crepin M, Caron P, Giraud S, Calender A, Buisine MP, Kerckaert JP, Porchet N 1999 Anovel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 84:1700-1704
169. Hoppner W, Ritter MM 1997 A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 6:587-590
170. Hoppner W, Dralle H, Brabant G 1998 Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A. Hum Mutat Suppl 1:S128-S130
171. Donis-Keller H 1995 The RET proto-oncogene and cancer. J Intern Med 238:319-325
172. Lips C, Landsvater RM, Hoppener J, Geerdink RA, Blijham G, Jansen-Schillhorn van Veen JM, van Gils J, de Wit MJ, Zewald RA, Berends M, Beemer FA, Brouwers-Smalbraak J, Jansen R, Ploos van Amstel HK, van Vroonhoven T, Vroom TM 1994 Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331:828-835
173. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM, Zajac JD, Robinson BG, Eng C 1997 Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82:3902-3904
174. Vandenbosch K, Renard M, Uyttebroeck A, Sciot R, Matthijs G, Legius E 2005 Medullary thyroid carcinoma in a child with a new RET mutation and a RET polymorphism. Genet Couns 16:95-100
175. Kasprzak L, Nolet S, Gaboury L, Pavia C, Villabona C, Rivera-Fillat F, Oriola J, Foulkes WD 2001 Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET. J Med Genet 38:784-787
176. Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P, Berti P, Basolo F, Ugolini C, Ciampi R, Nikiforov Y, Pinchera A 2004 Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab 89:5823-5827
177. Lesueur F, Cebrian A, Cranston A, Leyland J, Faid TM, Clements MR, Robledo M, Whittaker J, Ponder BA 2005 Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients. J Clin Endocrinol Metab 90:3454-3457
178. Lecube A, Hernandez C, Oriola J, Galard R, Gemar E, Mesa J, Simo R 2002 V804M RET mutation and familial medullary thyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriers. Surgery 131:509-514
179. Feldman GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW, Talpos GB, Roberson J, Petrucelli N, Jackson CE 2000 Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG3ATG) mutation. Surgery 128:93-98
180. Learoyd DL, Gosnell J, Elston MS, Saurine TJ, Richardson AL, Delbridge LW, Aglen JV, Robinson BG 2005 Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol (Oxf) 63:636-641
181. Diaz-Cano SJ, de Miguel M, Blanes A, Tashjian R, Wolfe HJ 2001 Germline RET 634 mutation positive MEN 2A-related C cell hyperplasias have genetic features consistent with intraepithelial neoplasia. J Clin Endocrinol Metab 86:3948-3957
182. Brooks AS, Oostra BA, Hofstra RM 2005 Studying the genetics of Hirschsprung's disease: unraveling an oligogenic disorder. Clin Genet 67:6-14
183. Brooks AS, Bertoli-Avella AM, Burzynski GM, Breedveld GJ, Osinga J, Boven LG, Hurst JA, Mancini GM, Lequin MH, de Coo RF, Matera I, de Graaff E, Meijers C, Willems PJ, Tibboel D, Oostra BA, Hofstra RM 2005 Homozygous nonsense mutations in KIAA1279 are associated with malformations of the central and enteric nervous systems. Am J Hum Genet 77:120-126
184. Amiel J, Lyonnet S 2001 Hirschsprung disease, associated syndromes, and genetics: a review. J Med Genet 38:729-739
185. Hansford JR, Mulligan LM 2000 Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 37:817-827
186. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C 1994 Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum Mol Genet 3:1259-1262
187. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BA 1996 Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 56:2167-2170
188. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG 1996 Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 44:249-257
189. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F 1996 Somatic mutations of the RET protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81:1619-1622
190. Bugalho MJ, Frade JP, Santos JR, Limbert E, Sobrinho L 1997 Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain. Eur J Endocrinol 136:423-426
191. Alemi M, Lucas SD, Sallstrom JF, Bergholm U, Akerstrom G, Wilander E 1997 A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma. Oncogene 14:2041-2045
192. Shirahama S, Ogura K, Takami H, Ito K, Tohsen T, Miyauchi A, Nakamura Y 1998 Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma. J Hum Genet 43:101-106
193. Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima A, Mitsuyama S, Iwashita T, Takahashi M 1999 Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Jpn J Cancer Res 90:1231-1237
194. Kalinin VN, Amosenko FA, Shabanov MA, Lubchenko LN, Hosch SB, Garkavtseva RF, Izbicki JR 2001 Three novel mutations in the RET proto-oncogene. J Mol Med 79:609-612
195. Jindrichova S, Kodet R, Krskova L, Vlcek P, Bendlova B 2003 The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma. J Mol Med 81:819-823
196. Ceccherini I, Pasini B, Pacini F, Gullo M, Bongarzone I, Romei C, Santamaria G, Matera I, Mondellini P, Scopsi L, Pinchera A, Pierotti MA, Romeo G 1997 Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene. Oncogene 14:2609-2612
197. Schilling T, Burck J, Sinn HP, Clemens A, Otto HF, Hoppner W, Herfarth C, Ziegler R, Schwab M, Raue F 2001 Prognostic value of codon 918 (ATG3ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95:62-66
198. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C 2002 Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466
199. Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL 2003 Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 95:1196-1204
200. Beldjord C, Desclaux-Arramond F, Raffin-Sanson M, Corvol JC, De Keyzer Y, Luton JP, Plouin PF, Bertagna X 1995 The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects. J Clin Endocrinol Metab 80:2063-2068
201. Lindor NM, Honchel R, Khosla S, Thibodeau SN 1995 Mutations in the RET protooncogene in sporadic pheochromocytomas. J Clin Endocrinol Metab 80:627-629
202. Yoshimoto K, Tanaka C, Hamaguchi S, Kimura T, Iwahana H, Miyauchi A, Itakura M 1995 Tumor-specific mutations in the tyrosine kinase domain of the RET proto-oncogene in pheochromocytomas of sporadic type. Endocr J 42:265-270
203. van der Harst E, de Krijger RR, Bruining HA, Lamberts SW, Bonjer HJ, Dinjes WN, Proye C, Koper JW, Bosman FT, Roth J, Heitz PU, Komminoth P 1998 Prognostic value of RET protooncogene point mutations in malignant and benign, sporadic phaeochromocytomas. Int J Cancer 79:537-540
204. Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L, Bocciardi R, Mondellini P, Scopsi L, Romeo G, Ponder BAJ, Pierotti MA 1995 RET activation by germline MEN2A and MEN2B mutations. Oncogene 11:2419-2427
205. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381-383
206. Carlomagno F, Melillo RM, Visconti R, Salvatore G, De Vita G, Lupoli G, Yu Y, Jing S, Vecchio G, Fusco A, Santoro M 1998 Glial cell line-derived neurotrophic factor differentially stimulates RET mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. Endocrinology 139:3613-3619
207. Arighi E, Popsueva A, Degl'Innocenti D, Borrello MG, Carniti C, Perala NM, Pierotti MA, Sariola H 2004 Biological effects of the dual phenotypic Janus mutation of RET cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease. Mol Endocrinol 18:1004-1017
208. Chiariello M, Visconti R, Carlomagno F, Melillo RM, Bucci C, de Franciscis V, Fox GM, Jing S, Coso OA, Gutkind JS, Fusco A, Santoro M 1998 Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene 16:2435-2445
209. Marshall GM, Peaston AE, Hocker JE, Smith SA, Hansford LM, Tobias V, Norris MD, Haber M, Smith DP, Lorenzo MJ, Ponder BA, Hancock JF 1997 Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase. Cancer Res 57:5399-5405
210. Freche B, Guillaumot P, Charmetant J, Pelletier L, Luquain C, Christiansen D, Billaud M, Manie SN 2005 Inducible dimerization of RET reveals a specific AKT deregulation in oncogenic signaling. J Biol Chem 280:36584-36591
211. Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M 2001 Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Res 61:1426-1431
212. Chappuis-Flament S, Pasini A, De Vita G, Segouffin-Cariou C, Fusco A, Attie T, Lenoir GM, Santoro M, Billaud M 1998 Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines. Oncogene 17:2851-2861
213. Mograbi B, Bocciardi R, Bourget I, Juhel T, Farahi-Far D, Romeo G, Ceccherini I, Rossi B 2001 The sensitivity of activated Cys Ret mutants to glial cell line-derived neurotrophic factor is mandatory to rescue neuroectodermic cells from apoptosis. Mol Cell Biol 21:6719-6730
214. Jhiang SM 2000 The RET proto-oncogene in human cancers. Oncogene 19:5590-5597
215. Lesueur F, Corbex M, McKay JD, Lima J, Soares P, Griseri P, Burgess J, Ceccherini I, Landolfi S, Papotti M, Amorim A, Goldgar DE, Romeo G 2002 Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma. J Med Genet 39:260-265
216. Stephens LA, Powell NG, Grubb J, Jeremiah SJ, Bethel JA, Demidchik EP, Bogdanova TI, Tronko MD, Thomas GA 2005 Investigation of loss of heterozygosity and SNP frequencies in the RET gene in papillary thyroid carcinoma. Thyroid 15:100-104
217. Ho T, Li G, Zhao C, Wei Q, Sturgis EM 2005 RET polymorphisms and haplotypes and risk of differentiated thyroid cancer. Laryngoscope 115:1035-1041
218. Ceccherini I, Hofstra RMW, Yin L, Stulp RP, Barone V, Stelwagen T, Bocciardi R, Nijveen H, Bolino A, Seri M, Ronchetto P, Pasini B, Bozzano M, Buys CHCM, Romeo G 1994 DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the RET proto-oncogene. Oncogene 9:3025-3029
219. Robledo M, Gil L, Pollan M, Cebrian A, Ruiz S, Azanedo M, Benitez J, Menarguez J, Rojas JM 2003 Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res 63:1814-1817
220. Baumgartner-Parzer SM, Lang R, Wagner L, Heinze G, Niederle B, Kaserer K, Waldhausl W, Vierhapper H 2005 Polymorphisms in exon 13 and intron 14 of the RET proto-oncogene: genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 90:6232-6236
221. Gimm O, Neuberg DS, Marsh DJ, Dahia PL, Hoang-Vu C, Raue F, Hinze R, Dralle H, Eng C 1999 Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 18:1369-1373
222. Ruiz A, Antinolo G, Fernandez RM, Eng C, Marcos I, Borrego S 2001 Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clin Endocrinol (Oxf) 55:399-402
223. Berard I, Kraimps JL, Savagner F, Murat A, Renaudin K, Nicolli-Sire P, Bertrand G, Moisan JP, Bezieau S 2004 Germline-sequence variants S836S and L769L in the RE arranged during Transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population. Clin Genet 65:150-152
224. Wiench M, Wloch J, Wygoda Z, Gubala E, Oczko M, Pawlaczek A, Kula D, Lange D, Jarzab B 2004 RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma. Cancer Detect Prev 28:231-236
225. Cebrian A, Lesueur F, Martin S, Leyland J, Ahmed S, Luccarini C, Smith PL, Luben R, Whittaker J, Pharoah PD, Dunning AM, Ponder BA 2005 Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6268-6274
226. Wohllk GN, Soto CE, Bravo AM, Becker CP 2005 G691S, L769L and S836S RET proto-oncogene polymorphisms are not associated with higher risk to sporadic medullary thyroid carcinoma in Chilean patients. Rev Med Chil 133:397-402
227. Borrego S, Wright FA, Fernandez RM, Williams N, Lopez-Alonso M, Davuluri R, Antinolo G, Eng C 2003 A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. Am J Hum Genet 72:88-100
228. Gath R, Goessling A, Keller KM, Koletzko S, Coerdt W, Muntefering H, Wirth S, Hofstra RM, Mulligan L, Eng C, von Deimling A 2001 Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease. Gut 48:671-675
229. Fitze G, Schierz M, Kuhlisch E, Schreiber M, Ziegler A, Roesner D, Schackert HK 2003 Novel intronic polymorphisms in the RET proto-oncogene and their association with Hirschsprung disease. Hum Mutat 22:177
230. Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, Eng C 1999 Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 36:771-774
231. Gimm O, Dziema H, Brown J, Hoang-Vu C, Hinze R, Dralle H, Mulligan LM, Eng C 2001 Over-representation of a germline variant in the gene encoding RET co-receptor GFRα-1 but not GFRα-2 or GFRα-3 in cases with sporadic medullary thyroid carcinoma. Oncogene 20:2161-2170
232. Borrego S, Fernandez RM, Dziema H, Japon MA, Marcos I, Eng C, Antinolo G 2002 Evaluation of germline sequence variants of GFRA1, GFRA2, and GFRA3 genes in a cohort of Spanish patients with sporadic medullary thyroid cancer. Thyroid 12:1017-1022
233. McWhinney SR, Boru G, Binkley PK, Peczkowska M, Januszewicz AA, Neumann HP, Eng C 2003 Intronic single nucleotide polymorphisms in the RET protooncogene are associated with a subset of apparently sporadic pheochromocytoma and may modulate age of onset. J Clin Endocrinol Metab 88:4911-4916
234. Kahraman T, de Groot JW, Rouwe C, Hofstra RM, Links TP, Sijmons RH, Plukker JT 2003 Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a. Eur J Surg Oncol 29:331-335
235. Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H 2005 Advances in the management of hereditary medullary thyroid cancer. J Intern Med 257:50-59
236. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells Jr SA 2005 Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353:1105-1113
237. Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H 2005 Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90:3999-4003
238. Gimm O, Ukkat J, Niederle BE, Weber T, Thanh PN, Brauckhoff M, Niederle B, Dralle H 2004 Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 28:1312-1316
239. Niccoli-Sire P, Murat A, Rohmer V, Gibelin H, Chabrier G, Conte-Devolx B, Visset J, Ronceray J, Jaeck D, Henry JF, Proye C, Carnaille B, Kraimps JL 2003 When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations? Surgery 134:1029-1036
240. Brauckhoff M, Gimm O, Weiss CL, Ukkat J, Sekulla C, Brauckhoff K, Thanh PN, Dralle H 2004 Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World J Surg 28:1305-1311
241. Decker RA, Geiger JD, Cox CE, Mackovjak M, Sarkar M, Peacock ML 1996 Prophylactic surgery for multiple endocrine neoplasia type IIa after genetic diagnosis: is parathyroid transplantation indicated? World J Surg 20:814-820
242. Dralle H, Gimm O, Simon D, Frank-Raue K, Gortz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R, Ritter MM, Spelsberg F, Heiss A, Hinze R, Hoppner W 1998 Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22:744-750
243. Wells Jr SA, Skinner MA 1998 Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 106:29-34
244. Lallier M, St Vil D, Giroux M, Huot C, Gaboury L, Oligny L, Desjardins JG 1998 Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome. J Pediatr Surg 33:846-848
245. Iler MA, King DR, Ginn-Pease ME, O'Dorisio TM, Sotos JF 1999 Multiple endocrine neoplasia type 2A: a 25-year review. J Pediatr Surg 34:92-96
246. Niccoli-Sire P, Murat A, Baudin E, Henry JF, Proye C, Bigorgne JC, Bstandig B, Modigliani E, Morange S, Schlumberger M, Conte-Devolx B 1999 Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC). Eur J Endocrinol 141:468-474
247. Sanso GE, Domene HM, Garcia R, Pusiol E, de M, Roque M, Ring A, Perinetti H, Elsner B, Iorcansky S, Barontini M 2002 Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C cell malignant disease in asymptomatic carriers. Cancer 94:323-330
248. Rodriguez GJ, Balsalobre MD, Pomares F, Torregrosa NM, Rios A, Carbonell P, Glower G, Sola J, Tebar J, Parrilla P 2002 Prophylactic thyroidectomy in MEN 2A syndrome: experience in a single center. J Am Coll Surg 195:159-166
249. Gill JR, Reyes-Mugica M, Iyengar S, Kidd KK, Touloukian RJ, Smith C, Keller MS, Genel M 1996 Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr 129:459-464
250. Jackson MB, Guttenberg M, Hedrick H, Moshang T 2005 Multiple endocrine neoplasia type 2A in a kindred with C634Y mutation. Pediatrics 116:468-471
251. Frohnauer MK, Decker RA 2000 Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 128:1052-1057
252. Machens A, Holzhausen HJ, Thanh PN, Dralle H 2003 Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134:425-431
253. Links TP, van Tol KM, Jager PL, Plukker JT, Piers DA, Boezen HM, Dullaart RP, de Vries EG, Sluiter WJ 2005 Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer 12:273-280
254. Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani G, Angeli A 2001 Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer 8:135-147
255. Lam MG, Lips CJ, Jager PL, Dullaart RP, Lentjes EG, van Rijk PP, de Klerk JM 2005 Repeated 131I-MIBG therapy in 2 patients with malignant pheochromocytoma. J Clin Endocrinol Metab 90:5888-5895
256. Putzer BM, Drosten M 2004 The RET proto-oncogene: a potential target for molecular cancer therapy. Trends Mol Med 10:351-357
257. Blaskovich MA, Lin Q, Delarue FL, Sun J, Park HS, Coppola D, Hamilton AD, Sebti SM 2000 Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nat Biotechnol 18:1065-1070
258. Sebti SM, Hamilton AD 2000 Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene 19:6566-6573
259. Cochran AG 2000 Antagonists of protein-protein interactions. Chem Biol 7:R85-R94
260. Schlessinger J 2002 Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110:669-672
261. Bennasroune A, Fickova M, Gardin A, Dirrig-Grosch S, Aunis D, Cremel G, Hubert P 2004 Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol Biol Cell 15:3464-3474
262. Ellington AD, Szostak JW 1990 In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-822
263. Cerchia L, Duconge F, Pestourie C, Boulay J, Aissouni Y, Gombert K, Tavitian B, de Franciscis V, Libri D 2005 Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 3:e123
264. Thiel K 2004 Oligo oligarchy: the surprisingly small world of aptamers. Nat Biotechnol 22:649-651
265. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037
266. Asai N, Iwashita T, Matsuyama M, Takahashi M 1995 Mechanism of activation of the RET proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15:1613-1619
267. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480
268. Sawyers CL 2002 Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J Clin Oncol 20:3568-3569
269. Cohen MS, Hussain HB, Moley JF 2002 Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132:960-966
270. Skinner MA, Safford SD, Freemerman AJ 2003 RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res 23:3601-3606
271. de Groot JW, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT, Links TP, Eggen BJ, Hofstra RM 2006 Cellular effects of imatinib on medullary thyroid cancer cells harboring mulitiple endocrine neoplasia type 2A and 2B associated RET mutations. Surgery 139:806-814
272. Lanzi C, Cassinelli G, Pensa T, Cassinis M, Gambetta RA, Borrello MG, Menta E, Pierotti MA, Zunino F 2000 Inhibition of transforming activity of the RET/PTC1 oncoprotein by a 2-indolinone derivative. Int J Cancer 85:384-390
273. Lanzi C, Cassinelli G, Cuccuru G, Zaffaroni N, Supino R, Vignati S, Zanchi C, Yamamoto M, Zunino F 2003 Inactivation of RET/PTC1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci 60:1449-1459
274. Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F 2004 Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 96:1006-1014
275. Sakamoto KM 2004 Su-11248 Sugen. Curr Opin Investig Drugs 5:1329-1339
276. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A, Santoro M 2002 The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 62:1077-1082
277. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A, Santoro M 2003 Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine (PP2). J Clin Endocrinol Metab 88:1897-1902
278. Carniti C, Perego C, Mondellini P, Pierotti MA, Bongarzone I 2003 PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting. Cancer Res 63:2234-2243
279. Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M, Santoro M 2004 Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23:6056-6063
280. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G 2004 AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64:4931-4941
281. Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW, Nelkin BD 2003 CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 63:5559-5563
282. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290
283. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J 2005 A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11:3369-3376
284. Wells SA, You Y, Lakhani V, Bauer M, Langmuir P, Headley D, Skinner MA, Morse M, Burch W, The use of ZACTIMA (ZD6474) in the treatment of patients with hereditary medullary thyroid carcinoma. Proc of American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics Philadelphia, 2005 (Abstract B248)
285. Tibes R, Trent J, Kurzrock R 2005 Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 45:357-384
286. Hennige AM, Lammers R, Hoppner W, Arlt D, Strack V, Teichmann R, Machicao F, Ullrich A, Haring HU, Kellerer M 2001 Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology 142:4441-4447
287. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, degli Uberti EC 2005 SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma. Endocrinology 146:2692-2698
288. Dancey J, Sausville EA 2003 Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296-313
289. Melisi D, Troiani T, Damiano V, Tortora G, Ciardiello F 2004 Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. Endocr Relat Cancer 11:51-68
290. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M 2006 BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326-334
291. Tamm I, Dorken B, Hartmann G 2001 Antisense therapy in oncology: new hope for an old idea? Lancet 358:489-497
292. Winter-Vann AM, Casey PJ 2005 Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 5:405-412
293. Vivanco I, Sawyers CL 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501
294. Schmelzle T, Hall MN 2000 TOR, a central controller of cell growth. Cell 103:253-262
295. Meric-Bernstam F, Mills GB 2004 Mammalian target of rapamycin. Semin Oncol 31:10-17
296. Cheson BD, Zwiebel JA, Dancey J, Murgo A 2000 Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol 27:560-577
297. Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R 2004 Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3:1533-1542
298. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM 2005 Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24:3236-3245
299. Kuntzen C, Sonuc N, De Toni EN, Opelz C, Mucha SR, Gerbes AL, Eichhorst ST 2005 Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res 65:6780-6788
300. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
301. Yano L, Shimura M, Taniguchi M, Hayashi Y, Suzuki T, Hatake K, Takaku F, Ishizaka Y 2000 Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase. Hum Gene Ther 11:995-1004
302. Drosten M, Frilling A, Stiewe T, Putzer BM 2002 A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery 132:991-997
303. Drosten M, Stiewe T, Putzer BM 2003 Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther 14:971-982
304. Parthasarathy R, Cote GJ, Gagel RF 1999 Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res 59:3911-3914
305. Borkhardt A 2002 Blocking oncogenes in malignant cells by RNA interference - new hope for a highly specific cancer treatment? Cancer Cell 2:167-168